The University of Texas at Austin’s Discovery to Impact initiative has introduced a new venture studio designed to develop startups that address key challenges, beginning with medical digital twin technology.
“We’re creating a new systematic process for launching startups out of UT’s research enterprise that brings the right infrastructure, resources and expertise together to enable faster innovation and product development,” said Mark Arnold, associate vice president of Discovery to Impact and managing director of Longhorn Ventures at UT. “It starts by focusing on a real-world need and then creates ventures with a supportive ecosystem around them that solves for that need with products and solutions that benefit our local, state and national economies and society at large.”
Medical digital twins are virtual models of a patient’s body or organs built using data. These models allow doctors to analyze an individual’s physiology more precisely, conduct noninvasive tests, and predict responses to specific treatments before they are performed. This approach supports more personalized care as opposed to generalized treatment methods.
“The market for computational medicine with the use of AI-enabled digital twin technology has the potential to revolutionize personalized patient care and impact how we treat some of the most prevalent medical diseases of our time, like heart disease, dementia and cancer,” said Charles “Charley” Taylor, professor of internal medicine at UT’s Dell Medical School and chair in computational medicine at the Oden Institute for Computational Engineering and Sciences. Taylor will guide the studio’s first venture; he is recognized for his work in artificial intelligence, machine learning, digital twin technology, and as co-founder of Heartflow Inc.
The venture studio model identifies unmet needs in the market. Full-time entrepreneurs work alongside university researchers to discover technologies that meet these needs. Promising solutions are tested further before being developed into ventures aimed at attracting investment through strong value propositions and product-market fit. This approach seeks to reduce risk while accelerating time-to-market compared to traditional startup paths.
“As a public university, it is important that we build public trust by maximizing the return on academic research investments. The venture studio model rigorously validates technology and market fit to ensure that public investments in research are efficiently translated into real-world solutions,” added Arnold.
Moving medical breakthroughs from discovery into Food and Drug Administration-cleared clinical services is known to be complex, costly, and slow. The UT model uses shared software infrastructure along with dedicated compliance, legal, and human resources support to lower operational costs. This setup aims to support rapid creation of startups across multiple health-related fields.
Health care will be the first sector targeted by this venture studio. Future sectors may follow as the program grows. Startups from this effort can access UT’s strengths in computational medicine research, its emerging medical center resources, entrepreneurship programs ranked among the top nationally, as well as capital from the $10 million UT Seed Fund.
“Through startup creation, commercial collaborations, and other pathways to market, Discovery to Impact is accelerating the translation of academic research and breakthrough ideas into products and businesses that can change the world,” said Arnold.
More information about Discovery to Impact can be found at discoverytoimpact.utexas.edu.
